Letters to the Editor

Use of Diuretics to Treat Hypertension in Diabetic Persons



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2004 Nov 1;70(9):1646-1648.

to the editor: I read with great interest the article, “New Developments in the Management of Hypertension,”1 in American Family Physician, which provides an excellent introduction to the management of this condition.

I am aware of the guidelines on offering diuretics as first-line therapy. However, I must take issue with the authors’ assertion that diuretics should be the first or second drug administered for the control of hypertension in patients who have diabetes. It has been long established that diuretics, especially thiazide diuretics, adversely affect glucose metabolism. Although lower doses of these medications have less of an adverse effect, many of these patients have more severe hypertension that requires maximal dosing of treatment strategies.2 The use of this class of medications can worsen glucose control unnecessarily because other treatment options exist.

REFERENCES

1. Magill MK, Gunning K, Saffel-Shrier S, Gay C. New developments in the management of hypertension. Am Fam Physician. 2003;68:853–8.

2. Vivian EM, Rubinstein GB. Pharmacologic management of diabetic nephropathy. Clin Ther. 2002;24:1741–56.

in reply: Dr. Hood raises an excellent point regarding thiazide diuretics and blood glucose control. This is an area of much controversy. The recommendations of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)1 and the American Diabetes Association (ADA)2 advocate the use of thiazide diuretics (usually in addition to an angiotensin-converting enzyme [ACE] inhibitor) in patients who have hypertension and diabetes. The highest dosages of thiazide diuretics used in the 16 major clinical trials published since 1990 (on which these recommendations are based) were 25 mg of chlorthalidone or hydrochlorothiazide.3 In a meta-analysis,4 an average 1 percent elevation in blood glucose levels was seen in patients taking thiazide diuretics at these dosages; this does not represent a clinically significant increase in most patients with diabetes.4 Dosages above 25 mg appear to contribute only to increases in adverse effects such as hypokalemia, and not to further improvements in blood pressure control.4 The JNC and the ADA also advise that most patients with diabetes will need three or four medications to bring blood pressures to the goal of less than 130/80 mm Hg, with thiazide diuretics providing complementary reductions in blood pressure when combined with ACE inhibitors, angiotensin-receptor blockers, and/or beta blockers.1,2 These statements do not support the use of the high or “maximal” dosages (50 mg or greater) of thiazide diuretics that have been associated with elevations in blood glucose, but do support the use of lower doses in combination with other agents to reach blood pressure goals.3

In terms of efficacy, thiazide diuretics have demonstrated the same or greater benefits on long-term outcomes of cardiovascular and cerebrovascular disease in patients with diabetes as in those who do not have diabetes, reflecting the higher cardiovascular risk seen in patients with diabetes.2,5 In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), patients who had diabetes had fewer cardiovascular events with diuretic treatment than with ACE inhibitor treatment.5 The mean increase in fasting glucose levels in all patients over the four years of ALLHAT was 3 mg per dL (0.17 mmol per L) in those receiving chlorthalidone compared with a 0.6 mg per dL (0.03 mmol per L) increase in those receiving amlodipine, and a 1.4 mg per dL (0.08 mmol per L) decrease in those receiving lisinopril. Interestingly, among patients without diabetes at the beginning of the trial, the average fasting glucose level in all treatment groups was greater than 100 (104.4 mg per dL [5.80 mmol per L], 103.1 mg per dL [5.72 mmol per L], and 100.5 mg per dL [5.58 mmol per L], respectively). These numbers meet the ADA criteria for the diagnosis of pre-diabetes, which is associated with adverse cardiovascular outcomes.

With the current dosages of thiazide diuretics being used in practice, the negative effect of the small increases in blood glucose levels is overshadowed by the beneficial effects seen in clinical trials using thiazides as part of the multidrug regimen that is required to achieve blood pressure control in most patients with diabetes.

REFERENCES

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52.

2. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2004;27:S15–35.

3. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534–44.

4. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: an analysis of 354 randomised trials. BMJ. 2003;326:1427

5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002;288:2981–97.

Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.


Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article